Cargando…

Clinical Application Evaluation of Elecsys(®) HIV Duo Assay in Southwest China

BACKGROUND: HIV/AIDS continues to be a serious health concern of morbidity and mortality globally, and novel HIV testing is still an important component of diagnosing HIV earlier and reducing the spread of HIV. The Elecsys(®) HIV Duo assay is a 4th generation assay that can detect both HIV-1 p24 ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Mei, Yang, Wenjuan, Shi, Wu, Tao, Chuanmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157638/
https://www.ncbi.nlm.nih.gov/pubmed/35663466
http://dx.doi.org/10.3389/fcimb.2022.877643
_version_ 1784718677544796160
author Yang, Mei
Yang, Wenjuan
Shi, Wu
Tao, Chuanmin
author_facet Yang, Mei
Yang, Wenjuan
Shi, Wu
Tao, Chuanmin
author_sort Yang, Mei
collection PubMed
description BACKGROUND: HIV/AIDS continues to be a serious health concern of morbidity and mortality globally, and novel HIV testing is still an important component of diagnosing HIV earlier and reducing the spread of HIV. The Elecsys(®) HIV Duo assay is a 4th generation assay that can detect both HIV-1 p24 antigen (Ag) and HIV-1/2 antibody (Ab) in parallel and show the subresults for the Ab and Ab units. OBJECTIVES: To evaluate the clinical performance of the Elecsys(®) HIV Duo assay on the new cobas E 801 analyzer using a large number of clinical samples from a population in southwest China. METHODS: We collected testing results and information from all patients in a large general hospital. All eligible clinical specimens were first analyzed using the Elecsys(®) HIV Duo assay. The test results are given either as reactive or nonreactive as well as in the form of a cutoff index (COI). All initially reactive specimens were retested in duplicate with a 3rd-generation kit. Supplementary tests were divided into Ab confirmation tests and HIV-1 nucleic acid tests. GraphPad Prism and Python were used for plotting, and SPSS 21.0 software was used for statistical analysis. RESULTS: A total of 186391 specimens were received, and 436 patients were confirmed to be positive for HIV. Among the 86 cases with contact history available, there were more males than females, and heterosexual transmission was the most common route of HIV infection. The Elecsys(®) HIV Duo assay displayed 99.94%, 99.93% and 99.98% specificity for inpatient, outpatient and physical examination patients, respectively. The median COI ratios of the false-positive group were significantly lower than those of the true-positive group. CONCLUSIONS: The Elecsys(®) HIV Duo test (Cobase801 analyzer) differentiates the detection of HIV-1 p24 Ag and HIV-1/2 Ab with high specificity and facilitates the diagnosis of patients with early HIV infection. Therefore, the Elecsys(®)HIV Duo test is used for differentiation of antigen and antibody reactivity, making it suitable for routine clinical diagnosis.
format Online
Article
Text
id pubmed-9157638
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91576382022-06-02 Clinical Application Evaluation of Elecsys(®) HIV Duo Assay in Southwest China Yang, Mei Yang, Wenjuan Shi, Wu Tao, Chuanmin Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND: HIV/AIDS continues to be a serious health concern of morbidity and mortality globally, and novel HIV testing is still an important component of diagnosing HIV earlier and reducing the spread of HIV. The Elecsys(®) HIV Duo assay is a 4th generation assay that can detect both HIV-1 p24 antigen (Ag) and HIV-1/2 antibody (Ab) in parallel and show the subresults for the Ab and Ab units. OBJECTIVES: To evaluate the clinical performance of the Elecsys(®) HIV Duo assay on the new cobas E 801 analyzer using a large number of clinical samples from a population in southwest China. METHODS: We collected testing results and information from all patients in a large general hospital. All eligible clinical specimens were first analyzed using the Elecsys(®) HIV Duo assay. The test results are given either as reactive or nonreactive as well as in the form of a cutoff index (COI). All initially reactive specimens were retested in duplicate with a 3rd-generation kit. Supplementary tests were divided into Ab confirmation tests and HIV-1 nucleic acid tests. GraphPad Prism and Python were used for plotting, and SPSS 21.0 software was used for statistical analysis. RESULTS: A total of 186391 specimens were received, and 436 patients were confirmed to be positive for HIV. Among the 86 cases with contact history available, there were more males than females, and heterosexual transmission was the most common route of HIV infection. The Elecsys(®) HIV Duo assay displayed 99.94%, 99.93% and 99.98% specificity for inpatient, outpatient and physical examination patients, respectively. The median COI ratios of the false-positive group were significantly lower than those of the true-positive group. CONCLUSIONS: The Elecsys(®) HIV Duo test (Cobase801 analyzer) differentiates the detection of HIV-1 p24 Ag and HIV-1/2 Ab with high specificity and facilitates the diagnosis of patients with early HIV infection. Therefore, the Elecsys(®)HIV Duo test is used for differentiation of antigen and antibody reactivity, making it suitable for routine clinical diagnosis. Frontiers Media S.A. 2022-05-18 /pmc/articles/PMC9157638/ /pubmed/35663466 http://dx.doi.org/10.3389/fcimb.2022.877643 Text en Copyright © 2022 Yang, Yang, Shi and Tao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Yang, Mei
Yang, Wenjuan
Shi, Wu
Tao, Chuanmin
Clinical Application Evaluation of Elecsys(®) HIV Duo Assay in Southwest China
title Clinical Application Evaluation of Elecsys(®) HIV Duo Assay in Southwest China
title_full Clinical Application Evaluation of Elecsys(®) HIV Duo Assay in Southwest China
title_fullStr Clinical Application Evaluation of Elecsys(®) HIV Duo Assay in Southwest China
title_full_unstemmed Clinical Application Evaluation of Elecsys(®) HIV Duo Assay in Southwest China
title_short Clinical Application Evaluation of Elecsys(®) HIV Duo Assay in Southwest China
title_sort clinical application evaluation of elecsys(®) hiv duo assay in southwest china
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157638/
https://www.ncbi.nlm.nih.gov/pubmed/35663466
http://dx.doi.org/10.3389/fcimb.2022.877643
work_keys_str_mv AT yangmei clinicalapplicationevaluationofelecsyshivduoassayinsouthwestchina
AT yangwenjuan clinicalapplicationevaluationofelecsyshivduoassayinsouthwestchina
AT shiwu clinicalapplicationevaluationofelecsyshivduoassayinsouthwestchina
AT taochuanmin clinicalapplicationevaluationofelecsyshivduoassayinsouthwestchina